OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 130 filers reported holding OCULAR THERAPEUTIX INC in Q3 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65,212 | -72.4% | 20,768 | -54.6% | 0.00% | -70.0% |
| Q2 2023 | $235,900 | -2.1% | 45,717 | 0.0% | 0.01% | -16.7% |
| Q1 2023 | $240,929 | -91.1% | 45,717 | -95.3% | 0.01% | -90.8% |
| Q4 2022 | $2,712,327 | -56.6% | 965,241 | -35.9% | 0.13% | -59.4% |
| Q3 2022 | $6,252,000 | +6.1% | 1,506,456 | +2.8% | 0.32% | +6.6% |
| Q2 2022 | $5,892,000 | -7.9% | 1,465,702 | +13.5% | 0.30% | +24.2% |
| Q1 2022 | $6,395,000 | -13.3% | 1,291,905 | +22.1% | 0.24% | -10.3% |
| Q4 2021 | $7,372,000 | -13.2% | 1,057,727 | +24.5% | 0.27% | -11.7% |
| Q3 2021 | $8,496,000 | -51.0% | 849,600 | -30.6% | 0.31% | -51.3% |
| Q2 2021 | $17,349,000 | -18.3% | 1,223,500 | -5.5% | 0.63% | -17.6% |
| Q1 2021 | $21,248,000 | -13.8% | 1,294,850 | +8.7% | 0.77% | -6.2% |
| Q4 2020 | $24,648,000 | – | 1,190,703 | – | 0.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 6,122,089 | $32,263 | 100.00% |
| Opaleye Management Inc. | 6,105,900 | $32,178,093 | 9.64% |
| DELTEC ASSET MANAGEMENT LLC | 1,913,612 | $10,084,735 | 2.49% |
| Knoll Capital Management, LLC | 200,000 | $1,504,000 | 2.32% |
| Endurant Capital Management LP | 512,744 | $2,702,161 | 1.39% |
| Knoll Capital Management, LLC | 95,800 | $504,866 | 0.78% |
| Covestor Ltd | 60,008 | $316 | 0.28% |
| Ikarian Capital, LLC | 200,000 | $1,054,000 | 0.24% |
| EAM Investors, LLC | 224,211 | $1,181,592 | 0.23% |
| Nebula Research & Development LLC | 22,474 | $118,438 | 0.21% |